- Home
- CAF vs CGEN Comparison
CAF vs CGEN Comparison
Compare CAF & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAF | CGEN |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.3M | 201.8M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | CAF | CGEN |
|---|---|---|
| Price | $15.64 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 11.0K | ★ 222.7K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.60 | $1.43 |
| 52 Week High | $21.41 | $3.24 |
Technical Indicators
Market Signals| Indicator | CAF | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 21.81 | 40.54 |
| Support Level | N/A | $1.58 |
| Resistance Level | $18.47 | $2.29 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 1.14 | 28.79 |
Price Performance
Historical ComparisonAbout CAF Morgan Stanley China A Share Fund Inc.
Morgan Stanley China A Share Fund Inc is the United States based non-diversified, closed-end management investment company. Its investment objective is to seek capital growth by investing a majority of its assets in A-shares of Chinese companies listed on the Shanghai and Shenzhen Stock Exchanges. Its portfolio of investments consists of investment in different sectors such as the aerospace and defense, banks, automobiles, household durables, media, pharmaceuticals, software and other sectors.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.